細胞和基因供應鏈服務市場規模、佔有率和成長分析：按服務類型、療法、溫度範圍、最終用戶和地區分類－2026-2033年產業預測

2024 年全球細胞和基因供應鏈服務市值為 28.9 億美元，預計到 2025 年將成長至 34.2 億美元，到 2033 年將成長至 131.2 億美元，在預測期（2026-2033 年）內複合年成長率為 18.3%。

全球細胞和基因供應鏈服務市場對於細胞、病毒載體和CRISPR組件等敏感生技藥品的有效運輸和儲存至關重要，這些生物製劑需要精心照顧才能維持療效。 CAR-T療法和基因編輯療法的商業化推動了需求的成長，進而促使對專業物流、即時追蹤和法規遵從解決方案進行大量投資。分散式生產模式的出現縮短了治療週期，透過將符合GMP標準的無塵室建在更靠近患者的地方，減少了運輸時間和物流成本。人工智慧驅動的自動化透過為產品分配數位ID來提高可追溯性，從而增強了整個供應鏈的信任和協作，實現了即時監控，並促進了相關人員之間的安全數據共用。

全球細胞和基因供應鏈服務市場的促進因素

隨著個人化醫療需求的成長，高效率的配送網路、專業的物流和完善的冷鏈管理變得至關重要。這服務供應商建立客製化解決方案，以確保產品在整個供應鏈中的完整性。這些需求推動了生物製藥公司與物流專家之間的合作，促進了包裝、追蹤技術和法規遵從方面的進步，從而共同推動了市場成長。隨著越來越多的製造商尋求值得信賴的合作夥伴來促進個人化醫療的交付，以患者為中心的理念正在推動對可追溯性和監控的可視化平台的投資，最終增強了人們對供應鏈生態系統的信心。

全球細胞和基因供應鏈服務市場的限制因素

全球細胞和基因供應鏈服務市場面臨著許多限制因素，其中最主要的限制因素是先進設備和專用材料高成本，而這些設備和材料對於生產和分銷流程至關重要。高昂的成本導致供應鏈合作夥伴的服務費用上漲，給往往預算不足以支付這些費用的中小型生技公司造成了財務障礙。因此，這些公司可能被迫依賴有限的資源，甚至完全放棄進入某些治療領域。這種財務負擔限制了市場參與企業的數量，阻礙了綜合供應鏈解決方案的普及，並最終抑制了市場成長，導致專案推出被推遲，直到成本條件更加有利為止。

全球細胞和基因供應鏈服務市場趨勢

全球細胞和基因供應鏈服務市場正呈現出顯著的策略合作趨勢，旨在提升營運效率和韌性。製造商正加強與物流供應商、受託研究機構(CRO) 和創新公司的合作，建立整合的供應鏈，從而簡化從生產到交付的流程。這些合作關係促成了對關鍵基礎設施（尤其是冷鏈物流）的共同投資，從而更好地滿足監管要求並提高產品可追溯性。透過發揮各自的優勢，該市場的相關人員可以建立一個強大且適應性強的網路，從而更有效地應對臨床需求的波動，加快創新療法的上市速度，並在最大限度減少跨區域運營中斷的同時保持成長。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球細胞和基因供應鏈服務市場規模：按服務類型分類

• 物流/運輸
• 保存/冷凍保存
• 包裝和標籤
• 個人識別和管理歷史記錄（轉帳歷史記錄）管理
• 供應鏈諮詢與支援服務

全球細胞和基因供應鏈服務市場規模：按治療方法分類

• 細胞療法
• 基因治療
• 細胞和基因聯合治療

全球細胞和基因供應鏈服務市場規模：按溫度範圍分類

• 室溫
• 冷藏
• 冷凍
• 極低溫度

全球細胞和基因供應鏈服務市場規模：按最終用戶分類

• 生物製藥和生物技術公司
• 合約研發生產組織（CDMO）
• 醫院和治療中心
• 研究機構和臨床試驗機構

全球細胞和基因供應鏈服務市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Thermo Fisher Scientific Inc.
• Cryoport, Inc.
• Quick Specialized Healthcare Logistics
• Catalent, Inc.
• Lonza Group AG
• Charles River Laboratories International, Inc.
• PCI Pharma Services
• AmerisourceBergen Corporation
• UPS Healthcare
• DHL Supply Chain
• FedEx Corporation
• World Courier Management Inc.
• Marken Limited
• BioLife Solutions, Inc.
• CSafe Global Co.
• Avantor, Inc.
• WuXi AppTec Co., Ltd.
• MilliporeSigma
• Almac Group Limited
• Parexel International Corporation

結論與建議

Global Cell And Gene Supply Chain Services Market size was valued at USD 2.89 Billion in 2024 and is poised to grow from USD 3.42 Billion in 2025 to USD 13.12 Billion by 2033, growing at a CAGR of 18.3% during the forecast period (2026-2033).

The global cell and gene supply chain services market is vital for the effective transportation and storage of sensitive biologics such as cells, viral vectors, and CRISPR components, which require meticulous handling to maintain efficacy. The rise in demand is driven by the transition of CAR-T therapies and gene-editing treatments to commercial use, prompting significant investment in specialized logistics, real-time tracking, and regulatory compliance solutions. Decentralized manufacturing models are emerging, positioning GMP-certified clean rooms closer to patients, thereby reducing transit times and logistics costs, while enhancing treatment timelines. AI-driven automation is enhancing traceability by providing a digital identity to products, enabling real-time monitoring, and facilitating secure data sharing among stakeholders, thereby strengthening confidence and collaboration throughout the supply chain.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell And Gene Supply Chain Services market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell And Gene Supply Chain Services Market Segments Analysis

Global cell and gene supply chain services market is segmented by service type, therapy type, temperature range, end user and region. Based on service type, the market is segmented into Logistics & Transportation, Storage & Cryopreservation, Packaging & Labeling, Chain of Identity & Chain of Custody Management and Supply Chain Consulting & Support Services. Based on therapy type, the market is segmented into Cell Therapy, Gene Therapy and Cell & Gene Combination Therapy. Based on temperature range, the market is segmented into Ambient, Refrigerated, Frozen and Cryogenic. Based on end user, the market is segmented into Biopharmaceutical & Biotechnology Companies, Contract Development & Manufacturing Organizations (CDMOs), Hospitals & Treatment Centers and Research Institutes & Clinical Trial Organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cell And Gene Supply Chain Services Market

The growing demand for personalized therapies necessitates the development of specialized logistics and robust cold chain management, alongside efficient distribution networks. This has led service providers to create customized solutions that maintain product integrity throughout the supply chain. Such needs promote collaboration between biopharmaceutical companies and logistics experts, driving advancements in packaging, tracking technologies, and regulatory compliance that collectively enhance market growth. As more manufacturers look for dependable partners to facilitate individualized treatment delivery, the emphasis on patient-centric approaches fuels investments in visibility platforms, which ensure traceability and monitoring, ultimately boosting confidence in the supply chain ecosystem.

Restraints in the Global Cell And Gene Supply Chain Services Market

The Global Cell and Gene Supply Chain Services market faces significant constraints due to the high costs associated with the advanced equipment and specialized materials essential for the manufacturing and distribution processes. These premium prices lead to increased service fees for supply chain partners, creating financial hurdles for smaller biotech companies that often lack sufficient budgets to cover these expenses. As a result, they may rely on their limited resources or opt out of pursuing certain therapeutic areas altogether. This financial strain restricts wider market participation and hinders the adoption of comprehensive supply chain solutions, ultimately stalling market growth and delaying project launches until more favorable cost conditions arise.

Market Trends of the Global Cell And Gene Supply Chain Services Market

The Global Cell and Gene Supply Chain Services market is witnessing a significant trend toward strategic partnerships aimed at enhancing operational efficiency and resilience. Manufacturers are increasingly collaborating with logistics providers, contract research organizations, and technology innovators to create integrated supply chains that facilitate smoother processes from production to delivery. These alliances allow for shared investments in critical infrastructure, particularly in cold-chain logistics, enabling better compliance with regulatory requirements and improved product traceability. By leveraging complementary strengths, stakeholders in this market can more effectively adapt to clinical demand fluctuations, expedite the arrival of innovative therapies to market, and foster robust, adaptable networks that sustain growth while minimizing disruption across diverse regions.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Cell and gene supply chain services Market Size by Service Type & CAGR (2026-2033)

• Market Overview
• Logistics & Transportation
• Storage & Cryopreservation
• Packaging & Labeling
• Chain of Identity & Chain of Custody Management
• Supply Chain Consulting & Support Services

Global Cell and gene supply chain services Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Cell Therapy
• Gene Therapy
• Cell & Gene Combination Therapy

Global Cell and gene supply chain services Market Size by Temperature Range & CAGR (2026-2033)

• Market Overview
• Ambient
• Refrigerated
• Frozen
• Cryogenic

Global Cell and gene supply chain services Market Size by End User & CAGR (2026-2033)

• Market Overview
• Biopharmaceutical & Biotechnology Companies
• Contract Development & Manufacturing Organizations (CDMOs)
• Hospitals & Treatment Centers
• Research Institutes & Clinical Trial Organizations

Global Cell and gene supply chain services Market Size & CAGR (2026-2033)

• North America (Service Type, Therapy Type, Temperature Range, End User)
  • US
  • Canada
• Europe (Service Type, Therapy Type, Temperature Range, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Service Type, Therapy Type, Temperature Range, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Service Type, Therapy Type, Temperature Range, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Service Type, Therapy Type, Temperature Range, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cryoport, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quick Specialized Healthcare Logistics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PCI Pharma Services
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AmerisourceBergen Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UPS Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DHL Supply Chain
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FedEx Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• World Courier Management Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Marken Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioLife Solutions, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSafe Global Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avantor, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MilliporeSigma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almac Group Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel International Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations